With childhood obesity on the rise, new options are making a difference
If you experience any suspected side effects from GLP-1 medications or fibre supplements, report them to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
Compared with other second-line options, DPP-4 inhibitors occupy a middle ground: SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) offer similar or slightly greater HbA1c reductions alongside additional cardiovascular and renal benefits
When weighing Sesame against competitors, the pricing transparency and provider choice stand out, but limited treatment options might feel restrictive
Are uncomfortable with compounded medications: If you have concerns about using medications that haven't undergone FDA review as finished products, or you strongly prefer FDA-approved options for peace of mind, brand-name Wegovy or Zepbound (if you can access them affordably) would be more appropriate than compounded formulations